{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T19:26:54Z","timestamp":1775676414941,"version":"3.50.1"},"reference-count":18,"publisher":"American Association for Cancer Research (AACR)","issue":"3","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,1]]},"abstract":"<jats:sec>\n                  <jats:title>Summary:<\/jats:title>\n                  <jats:p>While the current approach to precursor hematologic conditions is to \u201cwatch and wait,\u201d this may change with the development of therapies that are safe and extend survival or delay the onset of symptomatic disease. The goal of future therapies in precursor hematologic conditions is to improve survival and prevent or delay the development of symptomatic disease while maximizing safety. Clinical trial considerations in this field include identifying an appropriate at-risk population, safety assessments, dose selection, primary and secondary trial endpoints including surrogate endpoints, control arms, and quality-of-life metrics, all of which may enable more precise benefit\u2013risk assessment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-24-0022","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T14:26:10Z","timestamp":1709648770000},"page":"146-152","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-3092","authenticated-orcid":false,"given":"Irene M.","family":"Ghobrial","sequence":"first","affiliation":[{"name":"1Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6379-5101","authenticated-orcid":false,"given":"Nicole","family":"Gormley","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Food and Drug Administration, Silver Spring, Maryland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"4Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigaci\u00f3n del Cancer (IBMCC-USAL, CSIC), CIBER-ONC number CB16\/12\/00233, Salamanca, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1523-7388","authenticated-orcid":false,"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[{"name":"5Division of Hematology\/Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4024-8225","authenticated-orcid":false,"given":"Marta","family":"Chesi","sequence":"additional","affiliation":[{"name":"5Division of Hematology\/Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8249-5988","authenticated-orcid":false,"given":"Madhav V.","family":"Dhodapkar","sequence":"additional","affiliation":[{"name":"6Winship Cancer Institute of Emory University, Atlanta, Georgia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"3Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[{"name":"5Division of Hematology\/Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0936-0753","authenticated-orcid":false,"given":"Gad","family":"Getz","sequence":"additional","affiliation":[{"name":"7Broad Institute of MIT and Harvard, Cambridge, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8191-5832","authenticated-orcid":false,"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[{"name":"8Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4964-7476","authenticated-orcid":false,"given":"Sigurdur Y.","family":"Kristinsson","sequence":"additional","affiliation":[{"name":"9Faculty of Medicine, University of Iceland, Reykjav\u00edk, Iceland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7938-3950","authenticated-orcid":false,"given":"Jose Angel","family":"Martinez-Climent","sequence":"additional","affiliation":[{"name":"10Cancer Center Clinica Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16\/12\/00369, CB16\/12\/00489, Pamplona, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7653-711X","authenticated-orcid":false,"given":"Salomon","family":"Manier","sequence":"additional","affiliation":[{"name":"11Hematology Department, CHU Lille, Lille University, INSERM UMR-S1277, Lille, France."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9128-3012","authenticated-orcid":false,"given":"Catherine R.","family":"Marinac","sequence":"additional","affiliation":[{"name":"1Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5017-1620","authenticated-orcid":false,"given":"Francesco","family":"Maura","sequence":"additional","affiliation":[{"name":"12Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4271-6360","authenticated-orcid":false,"given":"Gareth J.","family":"Morgan","sequence":"additional","affiliation":[{"name":"13Myeloma Research Program, NYU Langone, Perlmutter Cancer Center, New York, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3971-2393","authenticated-orcid":false,"given":"Faith E.","family":"Davies","sequence":"additional","affiliation":[{"name":"13Myeloma Research Program, NYU Langone, Perlmutter Cancer Center, New York, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4124-4277","authenticated-orcid":false,"given":"Omar","family":"Nadeem","sequence":"additional","affiliation":[{"name":"1Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8334-1684","authenticated-orcid":false,"given":"Mario","family":"Nuvolone","sequence":"additional","affiliation":[{"name":"14Department of Molecular Medicine, University of Pavia, Pavia, Italy."},{"name":"15Fondazione IRCCS Policlinico San Matteo, Pavia, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-3815","authenticated-orcid":false,"given":"Bruno","family":"Paiva","sequence":"additional","affiliation":[{"name":"10Cancer Center Clinica Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16\/12\/00369, CB16\/12\/00489, Pamplona, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4042-1526","authenticated-orcid":false,"given":"Elizabeth","family":"O'Donnell","sequence":"additional","affiliation":[{"name":"1Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6115-8790","authenticated-orcid":false,"given":"Felipe","family":"Prosper","sequence":"additional","affiliation":[{"name":"16Hematology Service and Cell Therapy Unit and Program of Hematology-Oncology CIMA, Clinica Universidad de Navarra, Cancer Center Cl\u00ednica Universidad de Navarra (CCUN) and Instituto de Investigaci\u00f3n Sanitaria de Navarra (IdISNA), Pamplona, Spain."},{"name":"17Centro de Investigaci\u00f3n Biomedica en Red Cancer (CIBERONC) and RICORS TERAV, Madrid, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8419-1091","authenticated-orcid":false,"given":"Urvi A.","family":"Shah","sequence":"additional","affiliation":[{"name":"18Department of Medicine, Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8025-9850","authenticated-orcid":false,"given":"Romanos","family":"Sklavenitis-Pistofidis","sequence":"additional","affiliation":[{"name":"1Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"7Broad Institute of MIT and Harvard, Cambridge, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9369-4413","authenticated-orcid":false,"given":"Adam S.","family":"Sperling","sequence":"additional","affiliation":[{"name":"1Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George S.","family":"Vassiliou","sequence":"additional","affiliation":[{"name":"19Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom."},{"name":"20Department of Haematology, University of Cambridge, Cambridge, United Kingdom."},{"name":"21Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7344-9795","authenticated-orcid":false,"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[{"name":"1Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6408-5985","authenticated-orcid":false,"given":"Philip E.","family":"Castle","sequence":"additional","affiliation":[{"name":"22Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6418-0886","authenticated-orcid":false,"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"1Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9183-4857","authenticated-orcid":false,"given":"Jesus F.","family":"San Miguel","sequence":"additional","affiliation":[{"name":"10Cancer Center Clinica Universidad de Navarra (CCUN), Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC numbers CB16\/12\/00369, CB16\/12\/00489, Pamplona, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2024,5,1]]},"reference":[{"key":"2024050107060134700_bib1","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"2024050107060134700_bib2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"key":"2024050107060134700_bib3","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.1365-2141.2003.04654.x","article-title":"Smoldering multiple myeloma: natural history and recognition of an evolving type","volume":"123","author":"Rosi\u00f1ol","year":"2003","journal-title":"Br J Haematol"},{"key":"2024050107060134700_bib4","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.20.00437","article-title":"Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression","volume":"38","author":"Bustoros","year":"2020","journal-title":"J Clin Oncol"},{"key":"2024050107060134700_bib5","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1158\/1078-0432.CCR-22-1594","article-title":"Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma","volume":"28","author":"Termini","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2024050107060134700_bib6","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/s41375-022-01529-w","article-title":"Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio \u2265100","volume":"36","author":"Visram","year":"2022","journal-title":"Leukemia"},{"key":"2024050107060134700_bib7","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","article-title":"Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma","volume":"128","author":"Weinhold","year":"2016","journal-title":"Blood"},{"key":"2024050107060134700_bib8","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1038\/s41375-018-0153-6","article-title":"Multiple myeloma clonal evolution in homogeneously treated patients","volume":"32","author":"Corre","year":"2018","journal-title":"Leukemia"},{"key":"2024050107060134700_bib9","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","article-title":"Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial","volume":"17","author":"Mateos","year":"2016","journal-title":"Lancet Oncol"},{"key":"2024050107060134700_bib10","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.ccell.2022.10.017","article-title":"Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma","volume":"40","author":"Sklavenitis-Pistofidis","year":"2022","journal-title":"Cancer Cell"},{"key":"2024050107060134700_bib11","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"2024050107060134700_bib12","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.8001","article-title":"E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma","volume":"37","author":"Lonial","year":"2019","journal-title":"J Clin Oncol"},{"key":"2024050107060134700_bib13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejca.2022.07.030","article-title":"Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: a randomized, open-label study","volume":"174","author":"Mateos","year":"2022","journal-title":"Eur J Cancer"},{"key":"2024050107060134700_bib14","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/bloodadvances.2021005482","article-title":"Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials","volume":"6","author":"Kanapuru","year":"2022","journal-title":"Blood Adv"},{"key":"2024050107060134700_bib15","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"key":"2024050107060134700_bib16","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"key":"2024050107060134700_bib17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"key":"2024050107060134700_bib18","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S2352-3026(22)00386-6","article-title":"Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study","volume":"10","author":"Cowan","year":"2023","journal-title":"Lancet Haematol"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-24-0022\/3421653\/bcd-24-0022.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/5\/3\/146\/3449562\/146.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/5\/3\/146\/3449562\/146.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T07:06:37Z","timestamp":1714547197000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/5\/3\/146\/745083\/Round-Table-Discussion-on-Optimal-Clinical-Trial"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,5,1]]},"published-print":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-24-0022","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,1]]}}}